Oramed
CompanyIsrael
Oramed develops one asset, in phase 3 (insulin in asthma). Mostly protein or enzyme acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and glycolysis; based in Israel.
- 1
- Asset
- Furthest
- Phase 3
- 13
- Trials
- 0
- Signals
Pipeline
1Activates insulin receptors; intranasal delivery aims to enhance insulin signaling in the brain.
Phase 3, Protein or enzyme, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, asthma, chronic obstructive pulmonary disease
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms5
- Trials14
- Similar companies6
Updated 10 Oct 2026 · 39 sources